Nanoformulations for Delivering Small Molecules, Biologics, and Gene Modalities against Neurodegenerative Diseases/Disorders
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 196
Special Issue Editors
Interests: biomarkers; resistance; imaging; nanotechnology; long-acting therapeutics; diagnosis; liposomes; lipid nanoparticles
Interests: nanotechnology; immunotherapy; brain tumor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There is a great need for developing treatment modalities targeting neurodegenerative diseases and disorders. Novel modalities such as lipophilic prodrugs, antisense oligonucleotides, and CRISPR Cas9 systems have been explored as treatment strategies for neurodegenerative disorders such as Friedreich’s ataxia, Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, multiple sclerosis, Duchenne muscular dystrophy, tuberous sclerosis complex, Huntington’s disease. The FDA has testimonial emphasis for advancing such treatments, preliminarily focused on cures. Additionally, aggressive cancers such as glioblastoma multiforme (GBM), diffused intrinsic pontine glioma (DIPG), and ependymoma need curative therapeutic modalities with eventual benefits on prolonging progression-free survival and quality of life for the effected patients.
These goals will only be achieved by joining efforts from multiple disciplines including formulation and delivery scientists, geneticists, clinicians, immunologists, medicinal chemists, etc.
The aim of this Special Issue is to provide an adequate multidisciplinary platform for the interchange of valuable information (both basic and applied research) that aids in the development of novel gene delivery modalities such as mRNA vaccines, RNA/CRISPR Cas9 lipo/polyplex systems, and long-acting nanotherapeutics loading small molecules and biologics against diseases and disorders with genetic etiology.
As a Guest Editor of this Special Issue, I invite you to submit research articles, review articles, and short communications related to therapeutic mRNA, siRNA, miRNA lipid and polymeric nanoparticle vaccine delivery, combinatorial therapeutics loading biologics/small molecule inhibitors targeted towards amelioration, and the treatment of neurodegenerative diseases and disorders.
Dr. Dhruvkumar M. Soni
Dr. Héctor R. Méndez-Gómez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- gene therapy
- vaccines
- cancer
- biomarkers
- long-acting therapeutics
- CRISPR Cas9
- infectious diseases
